Animal health company ImmuCell Corp. (NASDAQ: ICCC) of Portland closed its full-year and fourth quarter 2015 with strong sales, which in turn created a backlog of orders for its First Defense product to prevent diarrhea and dehydration in newborn calves. Total sales increased 22% to $2.7 million in the fourth quarter of 2015 ended Dec. 31 compared to $2.2 million in the same period last year. That marked the 14th consecutive quarter of positive sales growth over the last 21 quarters compared to the same quarters the prior years. Net income in Q4 rose to $289,000, or 9 cents per diluted share, versus net income of $131,000, or 4 cents per diluted share, in 4Q2014. Read full story
Related Posts
Maine’s life sciences sector growth could outpace other industries
Maine’s $2.3 billion life sciences sector, which employed close to 10,000 people in 2024, will outpace the growth of many other...
IDEXX gets wiggle room to buy back more shares
IDEXX Laboratories Inc. (Nasdaq: IDXX), a Westbrook-based maker of veterinary diagnostics and software, has the green light from its board of...
Maine’s first accredited lab for PFAS testing is expanding to meet demand
NORRIDGEWOCK, Maine — This week, the Biden administration moved to prevent dangerous “forever chemicals” from being released onto the market after a less...